Microdosing psilocybin mushrooms involves taking a very small amount, typically 0.1 to 0.3 grams of dried material, on a repeating schedule over several weeks. The goal is a “sub-perceptual” dose: enough to influence brain chemistry but not enough to produce any noticeable psychedelic effects. While early research and large surveys suggest this practice may reduce symptoms of anxiety and depression, the evidence is still limited, and there are real safety considerations worth understanding before you start.
What Counts as a Microdose
A microdose of psilocybin mushrooms falls between 0.1 and 0.5 grams of dried mushroom material, with most practitioners landing in the 0.1 to 0.3 gram range. The upper end of that spectrum (around 0.5 grams) is where subtle perceptual shifts can begin, so most people aim lower. For context, a typical recreational dose starts around 2 to 3.5 grams, meaning a microdose is roughly one-tenth to one-twentieth of what someone would take to “trip.”
The challenge is consistency. Psilocybin content varies significantly between mushroom species, between individual mushrooms, and even between the cap and stem of the same mushroom. A 0.2 gram dose from one batch could be noticeably stronger or weaker than 0.2 grams from another. This is why most people grind their dried mushrooms into a fine, uniform powder before dosing. Grinding homogenizes the material so the psilocybin is more evenly distributed. From there, the powder is weighed on a milligram-precision scale (available for under $20) and packed into small capsules. This process gives you the most reliable dose-to-dose consistency possible with whole mushroom material.
Common Dosing Schedules
Two protocols dominate the microdosing world. The first, often called the Fadiman protocol after researcher James Fadiman, follows a three-day cycle: one day on, two days off. You take a microdose on day one, skip days two and three, then dose again on day four. The logic is that each dose produces a residual effect lasting one to two days afterward, so the off days aren’t entirely “empty.” A typical run lasts four to eight weeks, followed by a break of at least two to four weeks.
The second approach, popularized by mycologist Paul Stamets, involves dosing four days on followed by three days off. Stamets also advocates “stacking,” which means combining a psilocybin microdose with lion’s mane mushroom and niacin (vitamin B3). The idea is that lion’s mane supports nerve growth on its own, and niacin helps drive compounds to peripheral nerves. In one large survey of over 4,000 microdosers, about 39% reported adding lion’s mane to their microdose, and 18% added niacin.
Neither protocol has been rigorously tested against the other. Most people start with the Fadiman schedule because the extra rest days provide a buffer while you figure out how a given dose affects you.
What Happens in the Brain
When you ingest psilocybin, your body quickly converts it into psilocin, the compound that actually crosses into the brain. Psilocin binds primarily to serotonin receptors, particularly one called 5-HT2A, which plays a central role in mood, perception, and cognitive flexibility.
Research in large animal models has shown that even a single dose of psilocybin increases a marker of synaptic density in the hippocampus and prefrontal cortex, two brain regions heavily involved in emotional processing and the same regions where synaptic connections are reduced in people with major depression. This increase in synaptic density was detectable within one day of dosing and persisted for at least seven days. At the same time, psilocybin temporarily decreased the density of 5-HT2A receptors in those regions, a pattern researchers believe may contribute to antidepressant effects.
In plain terms, psilocybin appears to encourage the brain to form new connections between neurons while temporarily dialing down the sensitivity of the receptors it activates. Whether these same changes occur at microdose levels, rather than the larger single doses used in most lab studies, remains an open question.
What the Evidence Shows for Anxiety and Depression
A meta-analysis pooling nine studies on psilocybin and psychiatric conditions found a moderate-to-large positive effect on symptom reduction across depression, anxiety, PTSD, and substance use disorders, with an effect size of 0.77 on a random-effects model. That’s a meaningful number, roughly comparable to the effect sizes seen with established antidepressants in clinical trials.
However, most of the strongest evidence comes from studies using larger, supervised doses of psilocybin (typically 10 to 25 milligrams of synthetic psilocybin, equivalent to roughly 1.5 to 4 grams of dried mushrooms) rather than microdoses. The microdosing-specific research is more mixed. A double-blind, placebo-controlled study that used actual dried mushroom material found that people who microdosed reported improvements, but so did many people taking placebos. This “expectancy effect” is a recurring theme: people who believe they’re microdosing tend to feel better regardless of whether they received an active dose.
Large survey studies consistently report that microdosers have lower levels of anxiety and depression compared to non-microdosers, but surveys can’t tell us whether microdosing caused those differences or whether people with milder symptoms are simply more likely to try it.
Risks and Side Effects
Microdosing is often framed as low-risk because the doses are small, but there are several concerns worth taking seriously.
The most immediate physical effects are increased heart rate and a mild rise in blood pressure. These are dose-dependent, so they’re less pronounced at microdose levels, but they’re not absent. In surveys, a notable percentage of psychedelic users report occasional rapid heartbeat.
A more significant concern with long-term microdosing involves the heart valves. Psilocin has a high affinity for the 5-HT2B receptor, which is found in heart valve tissue. Chronic stimulation of this receptor has been linked to pathological valve remodeling in other drug classes (most famously with the diet drug fenfluramine). Because microdosing involves repeated exposure over weeks or months, some researchers have flagged it as a potential risk and suggested that regular microdosers should consider periodic echocardiographic monitoring. This risk is still theoretical for psilocybin specifically, but it’s grounded in well-established pharmacology.
Other commonly reported side effects include mild jitteriness, difficulty sleeping (especially if dosing later in the day), slight nausea, and occasional increases in emotional sensitivity that some people find uncomfortable rather than therapeutic.
Dangerous Drug Interactions
Because psilocybin works through the serotonin system, combining it with other serotonin-active medications creates real risks. The most dangerous documented interaction is with lithium: out of just six reported cases of lithium plus psilocybin, two resulted in seizures. If you take lithium, psilocybin is not safe for you at any dose.
SSRIs, SNRIs, tricyclic antidepressants, and MAOIs all modulate the same neurotransmitter pathways as psilocybin, raising the risk of serotonin syndrome, a potentially life-threatening condition involving agitation, rapid heart rate, high blood pressure, and in severe cases, seizures or loss of consciousness. SSRIs are the most commonly prescribed antidepressants in the world, which means many people interested in microdosing for depression are already taking a medication that interacts with psilocybin. Other medications of concern include trazodone, mirtazapine, buspirone, and atypical antipsychotics like risperidone.
Getting the Dose Right
If you’re starting from scratch, the standard advice is to begin at the low end (0.1 grams of dried, ground material) and stay there for at least one full cycle of your chosen protocol before adjusting. The goal is to feel essentially normal throughout the day. If you notice any visual changes, unusual body sensations, or a shift in perception, the dose is too high. Many people describe the ideal microdose as feeling like “a particularly good day” rather than anything distinctly altered.
Timing matters. Most people take their microdose in the morning with food, both to minimize nausea and to avoid any interference with sleep. Keeping a brief daily journal, even just a few words about mood, energy, and sleep quality, helps you track patterns over the weeks-long timeline where changes tend to emerge. Benefits from microdosing, when they occur, typically build gradually rather than appearing on the first dose day.
Legal Status
Psilocybin remains a Schedule I controlled substance under U.S. federal law. Oregon legalized psilocybin for mental health treatment in supervised settings starting in 2021, and Colorado followed in 2022 by decriminalizing psilocybin and legalizing supervised “healing centers” for adults 21 and older. In both states, the legal framework is built around supervised use, not personal possession for home microdosing. Several cities, including Denver, Oakland, and Washington D.C., have deprioritized enforcement of psilocybin laws, but deprioritization is not the same as legalization.
Australia became the first country to formally approve psilocybin as a prescription medication, allowing authorized psychiatrists to prescribe it for treatment-resistant depression starting in July 2023. In Canada, individual exemptions for psilocybin therapy can be granted through the federal health authority. In most other countries, psilocybin remains illegal, though enforcement varies widely.